Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors

本轮融资由新投资者贝恩资本生命科学、Forbion 和诺和控股联合领投，其他新老投资者也积极参与。

Proceeds to advance MC2 receptor antagonist OMS1620 through Phase 2 development and generate early clinical data for SLC15A4 inhibitor

推进MC2受体拮抗剂OMS1620进入二期临床开发，并为SLC15A4抑制剂生成早期临床数据

Oxford, United Kingdom – 15 October 2026 –

英国牛津 – 2026年10月15日 –

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company developing small molecule therapeutics against highly validated target ecosystems, today announced an oversubscribed $310 million (£230 million) Series C financing round. Proceeds from the financing will support the advancement of the Company’s lead program, OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist, through Phase 2 clinical development in congenital adrenal hyperplasia (CAH), as well as ACTH-dependent Cushing’s syndrome..

OMass Therapeutics（“OMass”或“公司”）是一家致力于针对高度验证的靶点生态系统开发小分子疗法的生物技术公司，今日宣布完成一轮超额认购的3.1亿美元（2.3亿英镑）C轮融资。融资所得将用于推进公司领先项目OMS1620的临床开发，OMS1620是一种潜在的同类最佳黑素皮质素2（MC2）受体拮抗剂，目前正开展针对先天性肾上腺皮质增生症（CAH）和促肾上腺皮质激素（ACTH）依赖性库欣综合征的二期临床试验。

The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with additional participation from Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences. Each of the Company’s existing investors also participated in the round, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and University of Oxford..

本轮融资由新投资者贝恩资本生命科学、Forbion 和 Novo Holdings 联合领投，Janus Henderson Investors、SV Health Investors 和 Jefferson Life Sciences 也参与了投资。公司现有投资者均参与了本轮融资，包括 Syncona、Oxford Science Enterprises、GV、Northpond Ventures、Sanofi Ventures、英国商业银行以及牛津大学。

OMS1620 has been designed to increase receptor residency time and maintain activity in the presence of rising endogenous ACTH levels. This can allow more patients with CAH to achieve androgen normalization while on physiologic doses of glucocorticoids.

OMS1620 旨在延长受体驻留时间，并在内源性 ACTH 水平升高的情况下维持活性。这使得更多先天性肾上腺皮质增生症（CAH）患者能够在生理剂量的糖皮质激素治疗下实现雄激素水平正常化。

The financing will also support OMass’ earlier-stage pipeline, including generation of initial clinical data for a potential first-in-class SLC15A4 inhibitor for lupus and other diseases associated with interferon overproduction and pathogenic B-cell activation.

该融资还将支持OMass的早期研发管线，包括为一种潜在的靶向SLC15A4的首创抑制剂生成初步临床数据，该抑制剂适用于狼疮及其他与干扰素过度产生和致病性B细胞活化相关的疾病。

“This financing comes at an exciting point in OMass’ evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow,”

“此次融资正值 OMass 发展进程中一个令人振奋的时刻，我们正在推进 OMS1620 进入临床试验阶段，而我们的 SLC15A4 抑制剂也蓄势待发，紧随其后。”

said Ros Deegan, Chief Executive Officer of OMass Therapeutics.

OMass Therapeutics 首席执行官 Ros Deegan 表示。

“We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programs in endocrinology and immunology into the clinic. With the backing of an outstanding group of new and existing investors, we are entering our next phase of growth with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients.”.

“我们已经证明了我们的团队和方法有能力发现并推进一系列内分泌学和免疫学领域的首创和同类最优项目进入临床阶段。在 outstanding 的新老投资者群体的支持下，我们正进入下一个增长阶段，拥有将这一进展转化为一系列具有临床差异化优势的药物组合的资源，以造福患者。”

In conjunction with the financing, Evan Greif of Bain Capital Life Sciences and Audrey Cacaly of Forbion will join the Company’s Board of Directors. Max Klement of Novo Holdings and Ali Jazayeri of SV Health Investors will receive Board observer seats.

作为此次融资的一部分，贝恩资本生命科学部门的 Evan Greif 和 Forbion 的 Audrey Cacaly 将加入公司董事会。Novo Holdings 的 Max Klement 和 SV Health Investors 的 Ali Jazayeri 将获得董事会观察员席位。

“OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs,”

“OMass 凭借经验丰富的团队和清晰的愿景，致力于打造一个领先的疗法公司，将复杂的生物学转化为针对存在重大未满足需求患者的差异化药物。”

said Evan Greif, Principal at Bain Capital Life Sciences.

贝恩资本生命科学公司负责人埃文·格雷夫表示。

“The Company is executing against that vision by advancing OMS1620 and applying its proprietary discovery approach to build a broader pipeline across endocrinology and immunology. We see meaningful potential for OMS1620 to improve the treatment for patients with CAH and look forward to partnering with Ros and the team to support the Company’s strategic and patient-first approach.”.

“公司正通过推进OMS1620的研发，并运用其专有的药物发现方法，构建覆盖内分泌学和免疫学的更广泛产品管线，从而践行这一愿景。我们认为OMS1620在改善先天性肾上腺皮质增生症（CAH）患者的治疗方面具有显著潜力，并期待与Ros及其团队合作，支持公司坚持战略导向和以患者为先的理念。”

“This financing has the potential to deliver clinical data for two differentiated programs, OMS1620 and SLC15A4, providing important opportunities to demonstrate their therapeutic potential,”

“此次融资有望为两个差异化项目OMS1620和SLC15A4提供临床数据，从而展示其治疗潜力的重要机会。”

said Audrey Cacaly, Principal at Forbion.

Forbion 的主管 Audrey Cacaly 表示。

“These programs are part of a pipeline built entirely through internal discovery, underscoring the productivity and breadth of OMass’ platform and its potential to generate meaningful new medicines across endocrine and immunologic diseases. We look forward to working closely with the talented OMass team as they advance these programs.”.

“这些项目是完全通过内部发现构建的研发管线的一部分，凸显了OMass平台的生产力和广度，以及其在内分泌和免疫疾病领域开发具有临床意义的新药的潜力。我们期待与才华横溢的OMass团队密切合作，共同推进这些项目。”

“We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic

“我们很高兴加入支持OMass的顶级投资者联盟，助力该公司将其突破性项目推进至临床试验阶段。”

,” said Max Klement, Partner, Venture Investments at Novo Holdings.

”诺和控股公司（Novo Holdings）风险投资合伙人马克斯·克莱门特（Max Klement）表示。

“Each of these candidates has the potential to address substantial unmet patient needs in their respective areas of endocrinology and immunology, and we look forward to the Company’s continuing progress.”

“这些候选药物中的每一个都有潜力在其各自的内分泌学和免疫学领域解决大量未满足的患者需求，我们期待公司继续取得进展。”

For further information, please contact:

如需更多信息，请联系：

OMass Therapeutics

OMass Therapeutics

Rosamond Deegan, Chief Executive Officer

罗莎蒙德·迪根，首席执行官

Email:

电子邮件：

ros.deegan@omass.com

ros.deegan@omass.com

Investor Relations

投资者关系

Renee Leck, THRUST

蕾妮·莱克，THRUST

Email:

电子邮件：

renee@thrustsc.com

renee@thrustsc.com

Media

媒体

Mary-Jane Elliott, Namrata Taak, Ashley Tapp ICR Healthcare

玛丽-简·埃利奥特、南姆拉塔·塔克、阿什利·塔普 ICR 医疗保健

Email: omass@icrhealthcare.com

电子邮件：omass@icrhealthcare.com

About OMass Therapeutics

关于 OMass Therapeutics

OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems. Its proprietary OdyssION™ drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques and custom chemistry to interrogate drug targets within their native ecosystems, providing cell-system fidelity with cell-free precision..

OMass Therapeutics 是一家生物技术公司，致力于针对高度验证的靶点生态系统开发小分子疗法。其专有的 OdyssION™ 药物发现平台结合了新一代天然质谱技术、新型生物化学技术和定制化学方法，在靶点的天然生态系统中对药物靶点进行探究，从而在无细胞体系的精确度下实现细胞系统的保真度。

OMass’ lead program, OMS1620, is a best-in-class MC2 (melanocortin-2) receptor antagonist for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome, designed to maintain efficacy in the presence of elevated ACTH levels. OMass is also advancing a broader preclinical pipeline including an SLC15A4 inhibitor for lupus and other indications related to interferon overproduction and pathogenic B-cell activation..

OMass 的领先项目 OMS1620 是一款同类最佳的 MC2（黑素皮质素-2）受体拮抗剂，用于治疗先天性肾上腺皮质增生症（CAH）和 ACTH 依赖性库欣综合征，旨在即使在高水平促肾上腺皮质激素（ACTH）存在的情况下也能保持疗效。OMass 还在推进更广泛的临床前研发管线，其中包括一种用于狼疮及其他与干扰素过度产生和致病性 B 细胞激活相关适应症的 SLC15A4 抑制剂。

Headquartered in Oxford, UK, OMass was founded as a spin-out from Professor Dame Carol Robinson’s lab at the University of Oxford to translate pioneering native mass spectrometry research into novel small molecule therapeutics against historically challenging targets. The Company is backed by a top-tier international investor syndicate..

OMass 总部位于英国牛津，是从牛津大学卡罗尔·罗宾逊女爵士教授的实验室衍生成立的公司，旨在将开创性的天然质谱研究转化为针对历来具有挑战性靶点的新型小分子疗法。该公司由一家顶级的国际投资者联盟支持。

To learn more, please visit

如需了解更多，请访问

www.omass.com

www.omass.com

. Follow us on

在 上关注我们

LinkedIn

领英

.

。